85 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
at Medical Meetings in US and Europe
◦Pediatric Endocrinology Society (PES)
◦10th International Congress of the Growth Hormone Research Society (GRS … combined 24-month data to be presented in Q2 2024
◦Two abstracts accepted for poster presentation at the Endocrine Society (ENDO) Annual Meeting
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
Endocrine Society (PES) o Growth Hormone Research Society (GRS) o European Congress of Endocrinology (ECE) o Data presented at these medical conferences … with significantly less exposure to circulating growth hormone. Phase 2 Data Presented at Medical Meetings o Endocrine Society Annual Meeting (ENDO) – 2
8-K
EX-99.1
LUMO
Lumos Pharma Inc
18 Apr 24
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4:53pm
Trials will be presented at several upcoming medical meetings in the US and Europe.
Pediatric Endocrine Society (PES) Annual Meeting, held May 2-5 … in a poster session, Friday, May 3rd, 12:15-1:45 PM CT
The 10th International Congress of the Growth Hormone Research Society (GRS), held May 10-11, 2024
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 Nov 23
Other Events
4:38pm
Endocrinology, University of Manchester. Prior member of Councils of GH Research Society, Society for Endocrinology UK, and European Society … dose of LUM-201 stim test Data presented at the 2021 Annual Meeting of The Endocrine Society and published online in the journal, Hormone Research
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
page in the Investors & Media section of the Company’s website.
OraGrowtH212 Trial Data Presented at the 2023 annual meeting of the European Society
8-K
EX-99.1
2sbm1bak
26 Sep 23
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
4:34pm
8-K
EX-99.1
v4e969ev21b
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.2
jcx ha34t0shwet56t
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.1
pqmc94j40lhh6lrrm81a
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.2
r62r2ovpz
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
j3jctztxso18j
8 May 23
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at
4:01pm
8-K
EX-99.1
mkc2x6s il
8 May 23
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at
4:01pm
8-K
EX-99.2
bxi 58e437y
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.1
9i2m 3omeeaa
3 May 23
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
4:49pm
8-K
EX-99.2
cf8jo7mv53ffht5tay6g
12 Dec 22
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
5:20pm
8-K
EX-99.1
c81lpv rsev4ictvytu
30 Nov 22
Other Events
6:27pm
8-K
EX-99.2
7j1k p0k7w9w7mb
14 Nov 22
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
6:55am
8-K
EX-99.1
occab85j
5 May 21
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:28pm
8-K
EX-99.1
99rbsjtcxu4lw qo
27 Apr 21
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
8:12am
8-K
EX-99.1
h6w5rgok
23 Mar 21
Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagogues
4:19pm